This study aims to see if adding **inotuzumab ozogamicin**, a special medicine that targets cancer cells, to usual chemotherapy can help patients with certain types of blood cancer, like **B-cell Acute Lymphoblastic Leukemia (B-ALL)**, **Mixed Phenotype Acute Leukemia (MPAL)**, and **B-lymphoblastic lymphoma (B-LLy)**. Chemotherapy is a treatment that uses drugs to kill cancer cells. The study will observe if patients do better with or without inotuzumab ozogamicin. Key drugs used include inotuzumab, a monoclonal antibody, and calicheamicin, a chemotherapy agent. Patients will undergo different phases of treatment, starting with Induction and Consolidation, followed by various maintenance phases. The study also checks if treating boys and girls for the same length of time works well and how to help patients stick to taking their medicine.

• Duration: Participation can last up to 2 years.
• Visits: Regular visits are required for treatment and follow-ups.
• Risks: Includes potential side effects from chemotherapy drugs.